News
-
-
PRESS RELEASE
Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), targeting muscle preservation in patients with obesity undergoing weight loss treatment with GLP-1 RAs -
PRESS RELEASE
Biophytis annonce le design de son étude clinique de phase 2 OBA dans l'obésité
Biophytis annonce le design de son ude clinique de phase 2 OBA dans l'ob sit e. La Soci t e se focalise sur le d fi m dical de l'ob sit e avec BIO101 (20-hydroxyecdysone) dans un traitement pour perdre du poids -
REGULATED PRESS RELEASE
Biophytis annonce le design de son étude clinique de phase 2 OBA dans l'obésité
Biophytis annonce le design de son étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone), visant à évaluer l'efficacité et la sécurité chez des patients obèses sous GLP-1 RAs -
REGULATED PRESS RELEASE
Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to test efficacy and safety for muscle function in obese patients. Study to start mid-2024 with results expected in 2025 -
-
-
PRESS RELEASE
May Revision: Multi-Year Continuous Medi-Cal Coverage for Young Children Not Funded
California organizations express frustration over lack of funding in the state budget to preserve Medi-Cal coverage for young children through multi-year continuous enrollment. Urging legislature for support -
-
